Amit Aysola is a managing director of Wanxiang Healthcare Investments, the corporate venturing subsidiary of Wanxiang America, a US-based subsidiary of China-headquartered automotive components producer Wanxiang.
The unit funds businesses developing healthcare technologies, with an emphasis on digital health. Since its inception in October 2016, Wanxiang Healthcare Investments has invested in 30 companies, focusing on late-seed to series C rounds.
Among the unit’s exits to date are Doctor.com, Limelight Health, Level EX and Livongo, which merged with Teladoc Health.
Wanxiang Healthcare Investments’ recent deals have included participation in a late-seed rounds of Carallel, a caregiver engagement solution, Watershed Health, a post-acute care analytics platform, Advocatia, a platform that simplifies benefits identification and entrollment, and DocStation, a workflow tool for that enables value-based care at pharmaciess.
Other portfolio businesses include Aclima, which measures hyperlocal air quality; Exo Imaging, a mobile point-of-care ultrasound solution; and OM1, which uses artificial intelligence to assist with personal health diagnoses.
Aysola has spent most of his career in healthcare. He has a master’s degree in biomedical engineering from University of Michigan but decided to approach the challenges facing the healthcare industry from a business, operations and technical perspective through his roles at Deloitte Consulting and Plan Data Management, a healthtech startup.
As well as his master’s degree, Aysola has an MBA from the Fuqua School of Business at Duke University.
